NMRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Neumora Therapeutics Inc (NMRA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows positive momentum with bullish technical indicators, hedge fund buying activity, and promising analyst upgrades. While the financials are weak, the potential blockbuster opportunity in Alzheimer's disease agitation and the positive Phase 1b results for NMRA-511 make this a strong speculative growth play.
The stock is showing bullish momentum with the MACD histogram above 0 and positively contracting, bullish moving averages (SMA_5 > SMA_20 > SMA_200), and a pre-market price of $3.55 above the pivot level of $3.325. RSI is neutral at 77.701, suggesting no overbought or oversold conditions.
Hedge funds are buying aggressively, with a 327.95% increase in buying activity over the last quarter.
Analyst upgrades with increased price targets and positive sentiment around NMRA-511's Phase 1b results for Alzheimer's disease agitation.
Potential blockbuster market opportunity for NMRA-511 with peak U.S. sales estimated at $1.8B.
Bullish technical indicators and strong options sentiment.
Weak financial performance, with a net income drop of -21.77% YoY and EPS down -22.22% YoY in Q3
No recent news or congress trading data to further validate sentiment.
High implied volatility (145.
may indicate increased risk.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net income loss of -$56.76M, down -21.77% YoY. EPS also declined to -0.35, down -22.22% YoY. The company has no gross margin, indicating it is still in the early stages of development.
Analysts have a positive outlook on NMRA, with William Blair upgrading the stock to Outperform and a net present value estimate of $7.62 per share. Mizuho also raised its price target to $6, citing encouraging Phase 1b results for NMRA-511 in Alzheimer's disease agitation. Both analysts highlight the potential blockbuster opportunity in this market.
